As of December 2021, several therapeutic treatments are available for mild-to-moderate COVID-19. These therapies are provided to states by the federal government and currently, supply of most of these therapies is extremely limited.
All of the therapies below have been authorized by the FDA for the treatment of COVID-19 in individuals ages 12 and over at risk for moderate to severe COVID-19 and in certain circumstances, such as those who are older or who are at higher risk due to certain medical conditions.
Please note: Due to the presence of the Omicron variant and consistent with federal guidance, two monoclonal antibody (mAb) therapies, bamlanivimab/etesevimab and casirivimab/imdevimab, should no longer be used at this time.
Sotrovimab – sotrovimab is a monoclonal antibody treatment which is administered by an intravenous (IV) infusion and should be given as early as possible after diagnosis and within 10 days after first symptom. Supply of Sotrovimab is very constrained at this time.
Paxlovid – Paxlovid is an oral medication in the form of a pill, available by prescription only to be initiated as soon as possible after a COVID-19 diagnosis and within 5 days after first symptom. Supply of Paxlovid is very constrained at this time.
Molnupiravir – molnupiravir is an oral medication in the form of a capsule by prescription only for treating mild-to-moderate COVID-19 as soon as possible after a COVID-19 diagnosis and within 5 days after first symptom. Supply of molupiravir is very constrained at this time.
Remdesivir – remdesiviris given as a series of 3 daily intravenous (IV) infusions for outpatients with mild-to-moderate COVID-19 within 7 days of symptom onset.
Supplies of sotrovimab, Paxlovid, and molnupiravir will be available from a subset of healthcare providers caring for individuals who are at highest risk for moderate to severe COVID-19. None of these treatments are currently authorized for use in individuals who have not been confirmed to be infected with COVID-19. Providers may purchase Remdesivir through the manufacturer. Remdesivir has also been approved by the FDA for treatment of hospitalized patients with COVID-19.
Neither mAb nor antiviral medications are a substitute for vaccination. Everyone is still encouraged to get vaccinated as soon as they can, whether it is a first, second or booster dose.
Information for patients
Several therapeutic treatments are now available for mild-to-moderate COVID-19. These therapies are provided to states by the federal government and currently, supply of most of these therapies is extremely limited.
Referral from a health care provider is required for patient treatment.
Treatment is offered regardless of immigration status or health insurance. Most treatments are free. Patients should discuss with their health care providers whether any of these treatments is right for them.